Abstract：【Objective】To investigate the long-term effect of tigrilol dual antiplatelet therapy after percutaneous coronary stenting (PCI) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACSC).【Methods】The clinical data of 500 patients diagnosed by coronary angiography and treated with PCI from May 2013 to January 2016 were retrospectively analyzed. The patients were divided into two groups: the observation group (n=256) and the control group (n=244). The patients in the observation group were treated with tigrello double antiplatelet therapy, and the control group were treated with routine double antiplatelet therapy. The biochemical indexes and left ventricular ejection fraction (LVEF) were observed and compared before and after treatment in the two groups. Adverse reactions and major adverse cardiovascular events within 2 years (MACEE) and bleeding events.【Results】After treatment, the levels of serum creatinine and LVEF in the two groups were significantly higher than those in the control group. The indexes of Cr and LVEF in the observation group was significantly higher than those in the control group (P<0.05). The serum creatine kinase isoenzyme (CK-MB), troponin I (cTnI) and platelet maximum aggregation rate (MPAR) in the two groups were significantly lower than those before treatment, and the decrease in the observation group was significantly higher than that in the control group (P<0.05). After 12 and 24 months follow-up, the incidence of total MACE and total haemorrhage events in the observation group was significantly lower than that in the control group, After 12 and 24 months follow-up, the incidence of total MACE and total haemorrhage events in the observation group was significantly lower than that in the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 11.33% (29/256) and in the control group was 14.75% (36/244).There was no significant difference in the incidence of adverse reactions between the two groups (χ2=1.296, P>0.05).【Conclusion】Tigrilol has a good inhibitory effect on platelet aggregation after PCI in patients with NSTE-ACS, and has a rapid effect. Stable drug effect does not increase the adverse reactions of patients. It can reduce the incidence of long-term MACE and is worthy of clinical application.
张桂霞,李大鹏,王环宇,张明亮,李志. NSTE-ACS患者PCI术后应用替格瑞洛双抗血小板治疗的2年追踪分析[J]. 医学临床研究, 2018, 35(4): 672-674,678.
ZHANG Gui-xia, LI Da-peng, WANG Huan-yu, et al. A 2-Year Follow-up Analysis of the Use of Ticagrelor Double Antiplatelet Therapy after PCI in Patients with NSTE-ACS. JOURNAL OF CLINICAL RESEARCH, 2018, 35(4): 672-674,678.
2018, Vol. 35 
